These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
720 related articles for article (PubMed ID: 29063517)
1. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517 [TBL] [Abstract][Full Text] [Related]
2. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. Okuma HS; Yonemori K Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689 [TBL] [Abstract][Full Text] [Related]
3. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
4. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer. Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182 [TBL] [Abstract][Full Text] [Related]
5. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466 [TBL] [Abstract][Full Text] [Related]
6. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. Tazzite A; Jouhadi H; Benider A; Nadifi S Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831 [TBL] [Abstract][Full Text] [Related]
7. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910 [TBL] [Abstract][Full Text] [Related]
8. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619 [TBL] [Abstract][Full Text] [Related]
9. Biology and Management of Patients With Triple-Negative Breast Cancer. Sharma P Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886 [TBL] [Abstract][Full Text] [Related]
10. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. Papadimitriou M; Mountzios G; Papadimitriou CA Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961 [TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors. Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793 [TBL] [Abstract][Full Text] [Related]
12. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904 [TBL] [Abstract][Full Text] [Related]
13. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. Chen Z; Wang X; Li X; Zhou Y; Chen K J Int Med Res; 2021 Feb; 49(2):300060521991019. PubMed ID: 33541181 [TBL] [Abstract][Full Text] [Related]
14. Emerging therapeutic modalities of PARP inhibitors in breast cancer. Wang X; Shi Y; Huang D; Guan X Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916 [TBL] [Abstract][Full Text] [Related]
15. Homologous recombination deficiency in triple negative breast cancer. Belli C; Duso BA; Ferraro E; Curigliano G Breast; 2019 Jun; 45():15-21. PubMed ID: 30818144 [TBL] [Abstract][Full Text] [Related]
16. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017 [No Abstract] [Full Text] [Related]
17. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer? Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921 [TBL] [Abstract][Full Text] [Related]
18. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline Desai NV; Tan AR JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718 [TBL] [Abstract][Full Text] [Related]
19. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Gupta T; Vinayak S; Telli M Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381 [TBL] [Abstract][Full Text] [Related]
20. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]